MA33571B1 - Traitement de cellules tumorales astrocytaires avec des inhibiteurs de recepteurs d'endotheline - Google Patents
Traitement de cellules tumorales astrocytaires avec des inhibiteurs de recepteurs d'endothelineInfo
- Publication number
- MA33571B1 MA33571B1 MA34671A MA34671A MA33571B1 MA 33571 B1 MA33571 B1 MA 33571B1 MA 34671 A MA34671 A MA 34671A MA 34671 A MA34671 A MA 34671A MA 33571 B1 MA33571 B1 MA 33571B1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- endotylene
- astrocytes
- receptor inhibitors
- macitentan
- Prior art date
Links
- 210000001130 astrocyte Anatomy 0.000 title 1
- 108091006082 receptor inhibitors Proteins 0.000 title 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 abstract 2
- 229960003065 bosentan Drugs 0.000 abstract 2
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 abstract 2
- 239000002308 endothelin receptor antagonist Substances 0.000 abstract 2
- 229960001039 macitentan Drugs 0.000 abstract 2
- JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 abstract 2
- 208000003174 Brain Neoplasms Diseases 0.000 abstract 1
- 206010059282 Metastases to central nervous system Diseases 0.000 abstract 1
- 239000012829 chemotherapy agent Substances 0.000 abstract 1
- 238000011393 cytotoxic chemotherapy Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1077—Beam delivery systems
- A61N5/1084—Beam delivery systems for delivering multiple intersecting beams at the same time, e.g. gamma knives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Environmental Sciences (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Abstract
La description concerne un antagoniste de récepteur d'endothéline à utiliser dans la prévention ou le traitement de métastases cérébrales en combinaison avec un agent cytotoxique de chimiothérapie, la radiothérapie ou les deux. L'antagoniste de récepteur d'endothéline peut être par exemple, le bosentan, le macitentan ou un mélange de bosentan et de macitentan.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23268709P | 2009-08-10 | 2009-08-10 | |
PCT/US2010/044832 WO2011019630A2 (fr) | 2009-08-10 | 2010-08-09 | Traitement de cellules tumorales astrocytaires avec des inhibiteurs de récepteurs dendothéline |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33571B1 true MA33571B1 (fr) | 2012-09-01 |
Family
ID=42938154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34671A MA33571B1 (fr) | 2009-08-10 | 2012-03-08 | Traitement de cellules tumorales astrocytaires avec des inhibiteurs de recepteurs d'endotheline |
Country Status (28)
Country | Link |
---|---|
US (2) | US8999934B2 (fr) |
EP (1) | EP2464218B1 (fr) |
JP (1) | JP2013501791A (fr) |
KR (1) | KR20120088665A (fr) |
CN (1) | CN102510719B (fr) |
AU (1) | AU2010282744B2 (fr) |
BR (1) | BR112012003103A2 (fr) |
CA (1) | CA2770397A1 (fr) |
CL (1) | CL2012000333A1 (fr) |
DK (1) | DK2464218T3 (fr) |
EA (1) | EA023864B1 (fr) |
ES (1) | ES2543280T3 (fr) |
HK (1) | HK1171336A1 (fr) |
HR (1) | HRP20150890T1 (fr) |
HU (1) | HUE026005T2 (fr) |
IL (1) | IL217915A0 (fr) |
IN (1) | IN2012DN01261A (fr) |
MA (1) | MA33571B1 (fr) |
MX (1) | MX2012001562A (fr) |
NZ (1) | NZ598078A (fr) |
PL (1) | PL2464218T3 (fr) |
PT (1) | PT2464218E (fr) |
SG (1) | SG178828A1 (fr) |
SI (1) | SI2464218T1 (fr) |
TN (1) | TN2012000054A1 (fr) |
TW (1) | TWI483938B (fr) |
WO (1) | WO2011019630A2 (fr) |
ZA (1) | ZA201200980B (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2965757A1 (fr) * | 2011-02-04 | 2016-01-13 | Actelion Pharmaceuticals Ltd. | Combinaisons contenant du macitentan destinées au traitement du glioblastoma multiforme |
CA2840170A1 (fr) | 2011-06-21 | 2012-12-27 | The Johns Hopkins University | Rayonnement focalise pour ameliorer les therapies basees sur l'immunite contre les neoplasmes |
BR112017018954A2 (pt) | 2015-03-06 | 2018-05-15 | Beyondspring Pharmaceuticals, Inc. | uso de forma mutante de proteína ras e método para tratar câncer |
EP3265091A4 (fr) * | 2015-03-06 | 2018-08-01 | Beyondspring Pharmaceuticals Inc. | Méthode de traitement d'une tumeur cérébrale |
MX2018000451A (es) | 2015-07-13 | 2018-05-07 | Beyondspring Pharmaceuticals Inc | Composiciones de plinabulina. |
MX2018001507A (es) | 2015-08-03 | 2018-09-18 | Enb Therapeutics Llc | Composiciones y metodos para tratar cánceres asociados con la activacion del etbr. |
JP6996728B2 (ja) * | 2016-01-07 | 2022-01-17 | 学校法人自治医科大学 | グルコーストランスポーター1発現用アデノ随伴ウイルスベクター |
MX2018009413A (es) | 2016-02-08 | 2019-05-15 | Beyondspring Pharmaceuticals Inc | Composiciones que contienen tucaresol o sus analogos. |
JP7122499B2 (ja) * | 2016-06-03 | 2022-08-22 | 幸久 村田 | がん転移阻害剤 |
EP3565812B1 (fr) | 2017-01-06 | 2023-12-27 | Beyondspring Pharmaceuticals, Inc. | Composés se liant à la tubuline et leur usage thérapeutique |
CA3052190A1 (fr) | 2017-02-01 | 2018-08-09 | Beyondspring Pharmaceuticals, Inc. | Methode de reduction de la neutropenie |
KR20200119246A (ko) | 2018-01-12 | 2020-10-19 | 이엔비 테라퓨틱스, 인크. | Etbr 활성화와 관련된 암을 치료하기 위한 중수소화 화합물, 조성물, 및 방법 |
CN112135614A (zh) | 2018-01-24 | 2020-12-25 | 大连万春布林医药有限公司 | 通过施用普那布林减少血小板减少症的组合物和方法 |
CN109232546B (zh) | 2018-09-25 | 2020-09-04 | 中国人民解放军总医院 | 一种嘧啶磺酰胺类衍生物的医药用途 |
CN112062857A (zh) * | 2019-06-10 | 2020-12-11 | 鸿运华宁(杭州)生物医药有限公司 | Eta抗体与bnp的融合蛋白质,及其药物组合物和应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2431675C (fr) * | 2000-12-18 | 2011-11-08 | Actelion Pharmaceuticals Ltd. | Nouveaux sulfamides et leur utilisation comme antagonistes du recepteur de l'endotheline |
GB0223854D0 (en) * | 2002-10-12 | 2002-11-20 | Astrazeneca Ab | Therapeutic treatment |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
ES2393117T3 (es) | 2005-09-12 | 2012-12-18 | Actelion Pharmaceuticals Ltd. | Composición farmacéutica estable que comprende una pirimidina-sulfamida |
CN101939001B (zh) | 2008-02-20 | 2012-06-20 | 埃科特莱茵药品有限公司 | 用于治疗卵巢癌的含有紫杉醇的组合 |
EP2965757A1 (fr) | 2011-02-04 | 2016-01-13 | Actelion Pharmaceuticals Ltd. | Combinaisons contenant du macitentan destinées au traitement du glioblastoma multiforme |
-
2010
- 2010-08-09 BR BR112012003103A patent/BR112012003103A2/pt not_active IP Right Cessation
- 2010-08-09 CA CA2770397A patent/CA2770397A1/fr not_active Abandoned
- 2010-08-09 KR KR1020127006203A patent/KR20120088665A/ko not_active Application Discontinuation
- 2010-08-09 DK DK10742690.0T patent/DK2464218T3/en active
- 2010-08-09 EP EP10742690.0A patent/EP2464218B1/fr not_active Not-in-force
- 2010-08-09 PL PL10742690T patent/PL2464218T3/pl unknown
- 2010-08-09 IN IN1261DEN2012 patent/IN2012DN01261A/en unknown
- 2010-08-09 NZ NZ598078A patent/NZ598078A/xx not_active IP Right Cessation
- 2010-08-09 CN CN201080040990.1A patent/CN102510719B/zh not_active Expired - Fee Related
- 2010-08-09 JP JP2012524769A patent/JP2013501791A/ja not_active Ceased
- 2010-08-09 TW TW099126507A patent/TWI483938B/zh not_active IP Right Cessation
- 2010-08-09 WO PCT/US2010/044832 patent/WO2011019630A2/fr active Application Filing
- 2010-08-09 EA EA201270264A patent/EA023864B1/ru not_active IP Right Cessation
- 2010-08-09 ES ES10742690.0T patent/ES2543280T3/es active Active
- 2010-08-09 SG SG2012009338A patent/SG178828A1/en unknown
- 2010-08-09 HU HUE10742690A patent/HUE026005T2/en unknown
- 2010-08-09 AU AU2010282744A patent/AU2010282744B2/en not_active Ceased
- 2010-08-09 US US13/390,072 patent/US8999934B2/en not_active Expired - Fee Related
- 2010-08-09 SI SI201031003T patent/SI2464218T1/sl unknown
- 2010-08-09 PT PT107426900T patent/PT2464218E/pt unknown
- 2010-08-09 MX MX2012001562A patent/MX2012001562A/es active IP Right Grant
-
2012
- 2012-02-02 IL IL217915A patent/IL217915A0/en unknown
- 2012-02-03 TN TNP2012000054A patent/TN2012000054A1/en unknown
- 2012-02-08 CL CL2012000333A patent/CL2012000333A1/es unknown
- 2012-02-09 ZA ZA2012/00980A patent/ZA201200980B/en unknown
- 2012-03-08 MA MA34671A patent/MA33571B1/fr unknown
- 2012-11-29 HK HK12112305.1A patent/HK1171336A1/xx not_active IP Right Cessation
-
2015
- 2015-03-06 US US14/640,662 patent/US20150352113A1/en not_active Abandoned
- 2015-08-20 HR HRP20150890TT patent/HRP20150890T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33571B1 (fr) | Traitement de cellules tumorales astrocytaires avec des inhibiteurs de recepteurs d'endotheline | |
CL2011000043A1 (es) | Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central. | |
MX2011008450A (es) | Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos. | |
MA32684B1 (fr) | Dérivés de picolinamide en tant qu'inhibiteurs de kinase | |
MA31663B1 (fr) | Dosage oral et interveineux de l'inhibiteur p2y12 reverisble et a action directe | |
MA52856B1 (fr) | Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4 | |
MX2013007622A (es) | Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson. | |
CL2011003347A1 (es) | Composicion farmaceutica que comprende un conjugado, correspondiente a benzoato de hidrocodona ; y uso en el tratamiento de una enfermedad, trastorno o afeccion mediada por la union de un opioide a receptores opioides. | |
MX363178B (es) | Compuestos de carbohidratos con funcion de galactosa para el tratamiento de la nefropatia diabetica y de los trastornos asociados. | |
NI201500059A (es) | Inhibidores de la tirosina-quinasa de bruton | |
ME01532B (me) | Jedinjenja | |
EA201270467A1 (ru) | Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты | |
MY163055A (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
TNSN08088A1 (en) | Substituted benzimidazoles as kinase inhibitors | |
MA35753B1 (fr) | Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2 | |
MA32132B1 (fr) | Utilisation de ranolazine pour traiter la douleur | |
MA38218A1 (fr) | Pyridine-2-amides utiles comme agonistes de cb2 | |
UA110213C2 (en) | Use of sigma-ligand induced opioid hyperalgesia | |
MX2010001449A (es) | Bromhidrato de bupropion y aplicaciones terapeuticas. | |
MA30330B1 (fr) | Association du mazindol dans le traitement du deficit de l'attention/hyperactivite | |
MX2011010782A (es) | Compuestos agonistas del receptor 5-ht4 para el tratamiento de trastornos cognitivos. | |
EA202091356A1 (ru) | A2a АНТАГОНИСТЫ КАК УСИЛИТЕЛИ КОГНИТИВНОЙ И МОТОРНОЙ ФУНКЦИЙ | |
BR112012014235A2 (pt) | tiazóis bicíclicos como moduladores alostéricos de receptores mglur5 | |
EA201390598A1 (ru) | Антагонист мутантного андрогенного рецептора | |
UA94055C2 (en) | Substituted benzimidazoles and methods of preparation |